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Background: The objective of this study was to evaluate a novel prostate endorectal immobilization system (EIS)
for improving the delivery of hypofractionated Stereotactic Ablative Body Radiotherapy (SABR) for prostate cancer.
Methods: Twenty patients (n = 20) with low- or intermediate-risk prostate cancer (T1-T2b, Gleason Score < 7,
PSA≤ 20 ng/mL), were treated with an EIS in place using Volumetric Modulated Arc Therapy (VMAT), to a prescription
dose of 26 Gy delivered in 2 fractions once per week; the intent of the institutional clinical trial was an attempt
to replicate brachytherapy-like dosimetry using SABR. EBT3 radiochromic film embedded within the EIS was
used as a quality assurance measure of the delivered dose; additionally, prostate intrafraction motion captured
using pre- and post-treatment conebeam computed tomography (CBCT) scans was evaluated. Treatment plans
were generated for patients with- and without the EIS to evaluate its effects on target and rectal dosimetry.
Results: None of the observed 3-dimensional prostate displacements were ≥ 3 mm over the elapsed treatment
time. A Gamma passing rate of 95.64 ± 4.28 % was observed between planned and delivered dose profiles on
EBT3 film analysis in the low-dose region. No statistically significant differences between treatment plans with-
and without-EIS were observed for rectal, bladder, clinical target volume (CTV), and PTV contours (p = 0.477,
0.484, 0.487, and 0.487, respectively). A mean rectal V80% of 1.07 cc was achieved for plans using the EIS.
Conclusions: The EIS enables the safe delivery of brachytherapy-like SABR plans to the prostate while having
minimal impact on treatment planning and rectal dosimetry. Consistent and reproducible immobilization of
the prostate is possible throughout the duration of these treatments using such a device.
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There is a growing body of evidence indicating that
prostate adenocarcinoma cells exhibit a low α/β ratio
suggesting sensitivity to hypofractionated doses of radi-
ation [1–3]. This has driven a recent trend towards
higher fractional doses in the form of Stereotactic Abla-
tive Body Radiotherapy (SABR), for localized prostate* Correspondence: ananth.ravi@sunnybrook.ca
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creativecommons.org/publicdomain/zero/1.0/cancer. A prospective clinical trial was started within
our institution prescribing 26 Gy to the prostate in 2
fractions, given one week apart, for patients with local-
ized disease (ClinicalTrials.gov ID: NCT02031328). The
intent of this trial was to replicate the dosimetric and
rectal tissue-sparing advantages of High Dose Rate
(HDR) brachytherapy-like SABR plans. Previous studies
have been successful in delivering HDR brachytherapy-like
SABR plans using CyberKnife [4]; however, limited access to
these specialized devices prevents widespread use of such
techniques. Increased access to brachytherapy-like SABR
treatments would result from an ability to deliverrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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(Linac) [5–9].
In HDR brachytherapy, sources are placed directly
within catheters implanted in the prostate, making pa-
tient and prostate motion relatively inconsequential to
treatment delivery. In SABR however, radiation dose is
delivered externally and accurate targeting hinges on
adding a safety margin, or planning target volume
(PTV), around the prostate to account for movement
and setup uncertainties [10]. The expansion of the treat-
ment volume in the vicinity of organs-at-risk (OAR), like
the bladder and rectum, may increase the risk of develop-
ing unacceptable late urinary and rectal complications,
particularly with such large fractional doses [11]. The
PTV margin may be confidently reduced if a method of
limiting the extent of prostate motion during treatment
was consistently possible. One proposed immobilization
strategy, and the focus of this study, is to address rectal
motion and filling, which has consistently been shown to
be a significant predicator of prostate motion [12, 13].
Endorectal balloons (ERB) have been used as a
method of controlling the volume and position of the
rectum and therefore indirectly immobilizing the pros-
tate [14–16]. While this strategy has generally demon-
strated efficacy in multi-fraction treatment regimens
there is some debate regarding the reproducibility of
positioning [17]; additionally, the process of inflating
the ERB raises the anterior surface of the rectum into
the high dose region of the treatment plan [18]. This
associated deformation of local anatomy makes it more
difficult to achieve the tighter dosimetric constraints
used in HDR brachytherapy [17–20]. While controversy
remains regarding the protective nature of the dis-
placed normal rectal tissue, it is generally agreed that
the dosimetric goal is to lower the dose to the rectal
volume as this results in lower rates of rectal toxicity
[10, 21–24]. An alternative to the ERB has been the use
of injectable/implantable spacers or polymeric gels. Al-
though the rectal doses using this system are lower due
to the physical separation of the prostate from the rec-
tum, no evidence is available that any substantial pros-
tate immobilizing effect is produced [25, 26]. These
methods are also quite invasive, requiring a transperi-
neal incision or interstitial needle placement, and intro-
duce additional departmental costs.
As part of the institutional clinical to replicate
brachytherapy-like dosimetry using a standard Linac a
prostate endorectal immobilization system (EIS) was
developed and evaluated with the intent of immobiliz-
ing the prostate gland during each treatment fraction.
The system is additionally capable of in-vivo quality as-
surance (QA) during treatment delivery using radio-
chromic EBT3 film. The aims of this study were to 1)
evaluate the effectiveness of the immobilization devicein limiting prostate intrafraction motion over the dur-
ation of treatment delivery; 2) to evaluate if plans with
similar dosimetric quality can be achieved with- and
without the EIS in place; and 3) to evaluate whether ac-
curate, in-vivo dose verification - as an additional dosi-
metric QA measure– is possible using the EIS.
Methods
A sample size of 20 patients, with low- or intermediate-
risk prostate cancer (T1-T2b, GS < 7, PSA ≤ 20 ng/mL),
were treated in a prospective, single-institution clinical
trial. Prescription dose was 26 Gy delivered in 2 frac-
tions once a week to the prostate clinical target volume
(CTV). Prospective planning was performed on Com-
puted Tomography (CT) data obtained during simula-
tion both with and without the EIS system. CT datasets
were obtained without-EIS as a) a precautionary meas-
ure in the event that patients were unable to tolerate the
EIS, b) stringent planning criteria were not achievable
with the EIS in place, and c) for dosimetric comparison
to EIS treatment plans. Patients excluded from the trial,
due to the previously stated criteria, were offered an
institution standard 35 Gy in 5 fraction SABR treatment
as an alternative. Retrospective data analysis of prostate
displacements that occurred during treatment was per-
formed using Conebeam Computed Tomography (CBCT).
Simulation & planning details
Three gold fiducial markers were implanted transperine-
ally under Transrectal Ultrasound (TRUS) guidance
prior to CT simulation to act as surrogates for prostate
position and to aid in daily image guidance. Patients
were instructed to have a comfortably full bladder and
also given a self-administered enema and simethicone
prior to the simulation process. CT scans were acquired
with the patient in a supine position with their legs sup-
ported in a custom-made Vac-lok mounted on a blue
Kneefix 2 (CIVCO Medical Soln., Coralville, IA, USA).
EIS immobilization system
The EIS system (Fig. 1) was mounted on the CT simula-
tor couch using a rigid carbon-fibre base. A mechanical
indexing system enabled the 5-degree-of-freedom transla-
tion and angulation of the probe. The probe was com-
posed of a USP class VI medical-grade photopolymer:
Accura® Clearvue™ (3D Systems, Inc., South Carolina,
USA). The radiographic properties of this material have
been previously validated by our group [27]. The probe
external diameter was of a similar size to a Transrectal
Ultrasound (TRUS) probe commonly used during HDR
brachytherapy image guidance – 20 mm (Transducer
Type 8848, Analogic Corporation, Boston, MA, USA) -
ensuring a consistent rectal diameter. Four small tungsten
beads were embedded within the probe to aid in CBCT
Fig. 1 Endorectal Immobilization System. 3D Mechanical drawing of
the EIS system highlighting the three main components of the system:
The carbon-fibre base (CB), the indexed mechanical system (IS), and
the probe apparatus (PR)
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mic EBT3 film (Covington, KY, USA) was also available.
The probe assembly was inserted with the patient lying ei-
ther supine or decubitus and then affixed to the indexing
system, and subsequently the base. A second CT scan was
then acquired without the EIS system in place. The tip of
the probe assembly was inserted to approximately mid-
gland before being affixed to the indexing system. In an
attempt to counteract the slight volume deformations pro-
duced with an intraluminal device, purposeful distension
of the rectum away from the high-dose regions posterior
to the prostate were applied with the intent of improving
rectal dosimetry. Typical distensions achieved were on the
order of 2–3 cm in the posterior direction with angula-
tions ranging from 10-25° posteriorly.
Pinnacle3 (version 9.2, Koninklijke Philips NV, Eindhoven,
Netherlands) was used for treatment planning. Prostate
contours were segmented on the CT simulation data set;
the clinical target volume (CTV) was equivalent to the
prostate contour and did not include proximal seminal
vesicles. A 3 mm isotropic expansion of the CTV was
used to generate a PTV margin. The selection of a 3 mm
isotropic PTV margin was primarily due to the reduction
in intrafraction prostate motion observed when transition-
ing from an IMRT to a VMAT delivery method; a center-
specific 5 mm margin for SABR patients receiving 35
Gy-in-5 fractions was therefore reduced to 3 mm to aid in
minimizing normal tissue toxicities [28]. In addition the
three gold fiducial markers were contoured as well as
OARs. OARs of interest included the bladder, rectum, and
small bowel. The rectal volume was delineated by con-
touring the entire rectum from the bottom of the ischium
to the sigmoid flexure (a length of approximately 11–
12 cm); the volume within the EIS probe apparatus, was
subtracted from the rectum contour to analyze only therectum wall and contents and not the probe material.
Without the aid of magnetic resonance (MR) imaging con-
touring the entire volume offered a conservative estimate
of the rectal membrane position for plan optimization as
opposed to approximating a rectal membrane. Both sets of
plans used “Smart Arc” optimization with the goal of main-
taining equal target coverage while minimizing rectal dose
parameters. Volumetric Modulated Arc Therapy (VMAT)
was used to treat the CTV to a prescription dose of 26 Gy
in 2 fractions (assuming an α/β ratio of 1.4 [2]), giving an
EQD2 (Equivalent dose when given in 2 Gy fractions) of
110 Gy [29, 30].
Treatment delivery
Patients were treated on an Elekta Beam Modulator with
a HexaPOD-enabled couch capable of roll, pitch, and
yaw corrections (Elekta AB, Stockholm, Sweden). Cone
Beam Computed Tomography scans were acquired directly
before and after the treatments to evaluate prostate intra-
fraction motion. CBCT datasets were first co-registered to
the EIS to verify position and depth; disagreements be-
tween positioning at treatment and that at planning
required fine manual adjustments to the probe depth to
bring the setup in accordance with the desired planning
position prior to treatment delivery. CBCT datasets were
then re-acquired and co-registered to the three fiducial
markers using a grey-value registration algorithm for
coarse positional adjustment and manual positioning re-
served for fine adjustment, followed by visual examination
of the prostate-rectum interface.
Intrafraction prostate displacement
Intrafraction prostate displacements were computed for
each patient by taking the difference between transla-
tions and rotations obtained from pre-treatment CBCT
and post-treatment CBCT co-registrations, respectively
[31]. Descriptive statistics (mean, standard deviation, 95 %
confidence interval (CI), and outlying data points), were
computed for each patient in the Left/Right (L/R), Super-
ior/Inferior (S/I), and Anterior/Posterior (A/P) transla-
tional axes. The magnitude of the intrafraction motion
was computed by summing the displacements in each
translational axis in quadrature. The magnitude of the
motion was plotted as inverse-cumulative frequency histo-
grams to determine the range of intrafraction motion for
all patients. In total 40 CBCT pre-post scan combinations
were examined.
Dosimetric analysis with- and without-EIS
A subset of patients (n = 10) were planned with and with-
out the EIS with the intent of evaluating its effects on dos-
imetry and plan quality. Plans were completed using the
same prescription dose with the intent of maintaining
similar target coverage; the impact on OAR dose, with
Fig. 2 Intrafraction prostate displacement with EIS. Inverse Cumulative
histogram of the 3D displacement, and left-right (L/R), superior-inferior
(S/I), and anterior-posterior (A/P) axis displacements. Less than 1 % of
3D displacements were greater than 2.9 mm, and no displacements
were≥ 3.0 mm. Similarly, no translational displacements were≥ 2.0 mm
in the L/R and A/P axes, and none were≥ 2.3 mm in the S/I axis
Nicolae et al. Radiation Oncology  (2015) 10:122 Page 4 of 8emphasis on the rectum, was then examined. Prostate
CTV and PTV coverage were examined using the con-
formity index and rectal and bladder V80% in cubic centi-
meters (cc) [7, 10]. Conformity indices were calculated
using the V100% and V85% divided by the CTV and PTV
volumes, respectively. The average Dose-Volume Histo-
gram (DVH) for each OAR and target with and without the
EIS was generated using the Computational Environment
in Radiation Therapy Research (CERR, ©2013, Deasy J)
software. A one-tailed Student’s t-test (significance level
α = 0.05), was used to evaluate differences between average
DVH curves for the CTV, PTV, rectum, and bladder for pa-
tients treated with- and without the EIS.
In-vivo rectal dosimetry
Using radiochromic film for patient specific quality assur-
ance is a proven method for ensuring the quality of deliv-
ered plans by measuring absolute dosimetry [32–34].
Films were evaluated after delivery of every fraction, as a
quality assurance measure of the delivered dose. 20,
150 mm × 38 mm GafChromic EBT3 film strips were
evaluated using FilmQA software (Ashland, Covington,
KY, USA). The irradiated film was compared to the dose
grid (generated from Pinnacle 3), taken in the plane of the
measured film. The in-plane dose grid was calculated by
software developed in-house. A Gamma index passing
rate with thresholds of 3 % and 3 mm was used in this
study to evaluate the agreement between the predicted




Intrafraction motion values were computed as mean ±
one standard deviation (SD), followed by the 95 % confi-
dence interval (CI). Negative values corresponded to
shifts in the right, inferior, and anterior directions. Intra-
fraction translational displacements were −0.20 ± 0.97 mm
(CI = ± 1.89 mm) in the L/R axis, −0.08 ± 1.40 mm (CI = ±
2.69 mm) in the S/I axis, −0.28 ± 1.04 mm (CI = ±
2.04 mm) in the A/P axis. The mean 3D displacement mag-
nitude was 1.83 ± 0.75 mm (CI = ±1.47 mm). Less than
5 % of 3D displacements were ≥ 2.87 mm, less than 1 %
were ≥ 2.90 mm and no displacements were ≥ 3.00 mm.
Similarly, in the L/R and A/P axes no displacements
were ≥2.00 mm and no displacements in the S/I axis
were ≥ 2.30 mm. These results are summarized in Fig. 2.
With- and without-EIS dosimetric analysis
Figure 3(a & b) presents the average DVH results with-
and without the EIS for the prostate contour (CTV and
PTV) for 10 patient plan sets. Figure 3(c) presents the
average DVH results for the rectum contour in absolute
volume (cubic centimeters), and Fig. 3(d) presents theaverage DVH results with and without the EIS for the
bladder contour. No statistical differences were evident
between the dosimetry with and without the EIS for the
bladder, rectum, CTV and PTV (p = 0.477, 0.484, 0.487,
and 0.487, respectively). Similarly, the average CTV
conformity index was 1.11 ± 0.03 for both groups; the
average PTV conformity index was 1.13 ± 0.03 and 1.12 ±
0.03 for the groups with- and without- EIS, respectively. A
transverse representation of the calculated dose distribu-
tions near the prostate midplane for both sets of plans can
be found in Fig. 4.
In-vivo film analysis
Evaluation of in-vivo, irradiated EBT3 films demonstrated
an average gamma passing rate of 95.64 ± 4.28 %. Figure 5
shows a sample dose-profile for a single patient comparing
our predicted planar dose model (derived from Pinnacle 3),
on the longitudinal film axis to the same axis on the irradi-
ated film. Despite the inevitable small deviations in probe -
and therefore EBT3 film plane - alignment from that at
planning comparable dose profiles were obtained in the re-
gion of high-dose gradient posterior to the treated volume.
Discussion
A comparison of prostate motion observed between pa-
tients treated using the EIS and those using the ERB, one
of the most common prostate immobilization methods, is
unavoidable. A similar mono-institutional study conducted
at our centre evaluated 30 intermediate-risk prostate can-
cer patients treated with a single SABR boost, using
VMAT, in dose-escalation (10 Gy, 12.5 Gy, and 15Gy)
[36]. In that study an ERB was used for prostate
immobilization during the treatment and CBCT image
guidance utilized to measure intrafraction prostate motion.
This trial showed 3D prostate displacements of 2.61 ±
1.50 mm (CI = ± 3.10 mm) [36]. In comparison, 3D
Fig. 3 Target and OAR doses with- and without-EIS. a & b Comparison of average Dose-Volume Histogram (DVH) results for 10 patients planned with-
and without EIS (dashed lines). Prescription is 26 Gy≥ 99 % to the clinical target volume (CTV) and 22 Gy≥ 99 % to the planning target volume (PTV),
respectively. Average DVH results for the Rectal (c), and Bladder (d), contour with- and without EIS are also presented. Standard deviation bands (1SD)
are displayed as grey areas (without EIS), and hatched areas (with EIS). Overlapping standard deviation bands are displayed as grey
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the EIS were significantly smaller at 1.83 ± 0.75 mm (CI = ±
1.47 mm), following a two-tailed Student’s t-test (p = 0.023,
significance level α= 0.05). The fractional dose, and there-
fore treatment time was comparable for both studies: 13 Gy
per fraction compared to patients stratified into doses
ranging from 10–15 Gy per fraction, both at > 6-min treat-
ment times. None of the treated fractions had 3D displace-
ments≥ 3 mm in the current study. These results are
comparable with a number of publications using endorectalFig. 4 Sample treatment plans of patients treated with- and without-EIS. a
the EIS (purple). Displayed are the prostate CTV (orange), and PTV (blue), as
105 % (maroon), 100 % (red), 95 %(dark blue), 85 % (green), and 50 % (ligh
prescription dose is 2600 cGyballoons for prostate immobilization, summarized in Table 1.
In essence, this method offered robust and consistent intra-
fraction immobilization, highly comparable to that of the
ERB, and with minimal changes as a function of increased
treatment times. It is hypothesized that the underlying
mechanism behind this immobilization was the direct fix-
ation of the rectum to the treatment couch, which addition-
ally limited any involuntary pelvic movement by patients.
One of the limitations of the intrafraction motion study was
the use of pre- and post-CBCT methods for evaluation.Treatment plan showing isodose distribution for patient treated with
well as the overall rectal contour. Percent isodose lines displayed are
t blue). b Isodose distribution for a patient treated without the EIS. CTV
Fig. 5 Longitudinal dose profile for EBT3 film sample. Absolute dose for
a single patient as a function of the longitudinal film length plotted
against the computed dose model. Good agreement was seen between
EBT3 and the treatment planning system (TPS) model for the first and
second fractions (Fr). Slight differences in curves were likely due to minute
changes in EIS positioning from that at planning
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over the treatment duration, and in fact may be somewhat
random in nature, the net displacement of the prostate over
the treatment duration may potentially be underestimated
using a pre-post imaging design [37]. Cine-MRI, now avail-
able at our center, has been shown to be an effective method
for live-tracking of prostate intrafraction motion [38]. A
valuable follow-up study would involve using cine-MRI to
verify the displacement results obtained in this study by
tracking the prostate motion over the elapsed treatment
time, thereby eliminating the temporal limitations imposed
by the pre-post CBCT-determined motion.
Similar studies reporting on the use of rectal retraction
as a means of limiting rectal dose demonstrated improved
dosimetry [39, 40]; however, in the present study the differ-
ences between clinically relevant CTV, PTV, rectum and
bladder dosimetric parameters with and without the EIS
system were minimal (Fig. 3). Absolute volume of irradi-
ated tissue was evaluated to provide a point-of-comparison
to HDR brachytherapy and has also been found to better
approximate the extent of rectal toxicities, which are
volume-dependent [11]. As noted previously the diameter
of the EIS probe was similar to the 20 mm diameter TRUS
probes used in ultrasound-guided HDR brachytherapy pro-
cedures, this similarity ensured that average rectal volumes
as well as distension were roughly identical. With similar
average rectal volumes during SABR (with the EIS inTable 1 Comparing prostate intrafraction motion magnitude. Prosta
using an endorectal balloon (ERB) for immobilization compared to t
showed significantly reduced 3D intrafraction motion for treatment
Study Sample size (n) Technique Immobilization
Current study 20 VMAT EIS
Chiang et al. 2014 [36] 30 VMAT ERB
Smeenk et al. 2012 [15] 30 IMRT ERB
Wang et al. 2012 [34] 30 IMRT or VMAT ERB
Both et al. 2011 [14] 24 IMRT or VMAT ERBplace), and HDR brachytherapy (with a TRUS in place), the
primary contributor to the amount of rectal tissue exposed
to high doses of radiation was the positioning of the rec-
tum. Posterior retraction away from the high-dose region
is applied during treatment with an EIS in order to
minimize rectal dose. During HDR brachytherapy com-
pression of the rectum towards the high-dose region is
required in order to obtain adequate image quality, this
should theoretically increase the dose to the rectum. How-
ever, as a result of the rapid dose fall-off in HDR brachy-
therapy the volumes of rectal tissue within the high dose
region were comparable between both treatment modal-
ities. The mean rectal volumes obtained by excluding the
EIS lumen from the rectal volume analysis (66.7 cc vs.
69.4 cc for plans with and without EIS, respectively) were
comparable. The rectal V80% was lower for plans with the
EIS with a mean value of 1.07 cc, and 1.27 cc for plans
without the EIS; however, these differences were statisti-
cally insignificant. The rectal V80% values are comparable
to similar HDR brachytherapy regimens, which typically
aim to achieve a rectal V80% < 1 cc [7]. In order for the
SABR-with-EIS treatment plans to approach a rectal
V80% typically achieved using HDR brachytherapy an ad-
vantageous retraction away from the high-dose region is
required.
With use of an ERB there is an associated increase in
dose delivered to the anterior rectal mucosa; this was
not evident with the use of the EIS system as the volume
of anterior rectal mucosa receiving the higher doses was
reduced by distending the rectum away from the pros-
tate. This has the added benefit of simultaneously in-
creasing the distance of the posterior rectal mucosa
from the high-dose region, potentially further reducing
the overall rectal dose. Future evaluations of the EIS sys-
tem will use MR imaging to define rectal contours with
improved accuracy and provide better estimates of the
impact on rectal dosimetry, potentially providing more
concrete evidence of this phenomenon. From this study
it was observed that target immobilization can be
achieved using the EIS system without compromising
target and OAR dosimetry; thereby, allowing the delivery
of ablative treatments with brachytherapy-like rectal tis-
sue sparing.te intrafraction motion results from multiple institutional trials
he current study using an EIS. Patients treated with the EIS
times longer than 6 min. EM = Electromagnetic
Motion Evaluation 3D intrafraction motion Treatment time (min)
Pre-post CBCT 0 % > 3 mm >6
Pre-post CBCT 3.7 % > 4.5 mm >6
Real-time EM tracking 7.0 % > 3 mm <6
Real-time EM tracking 5.0 % > 3 mm ≤6
Real-time EM tracking 5.2 % > 3 mm <6
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without a number of quality assurance measures in place
is potentially problematic: accurate delivery of dose to the
target and avoidance of critical structures is typically eval-
uated during follow-up by patient-reported side-effects
scores. To provide a more objective in-vivo dose monitor
during treatment a QA measure was directly incorporated
into the EIS system to ensure that the calculated treat-
ment plans were being accurately delivered. This was
achieved using EBT3 radiochromic film measurements.
High dose resolution (up to about 10 Gy) is possible using
EBT3 films and was therefore well-suited to measuring
the rapid dose gradient of the SABR distribution [31–34].
Despite the small probe positioning deviations previously
discussed the vast majority of films showed good agree-
ment with the Pinnacle3-determined planar dose (average
gamma passing rate > 95.64 ± 4.28 %). These results are
comparable to generalized Intensity Modulated Radiation
Therapy (IMRT) plans evaluated in phantoms using simi-
lar quality metrics [41]. Figure 5 shows an example of a
typical dose profile obtained during treatment relative to
the computed planar dose in Pinnacle3, good spatial
agreement in the longitudinal central-axis of the film was
evident. Measurement of the low doses received by the
film with known spatial orientation relative to the high-
dose treatment volume was relatively robust to minor var-
iations in probe positioning.
Conclusions
The novel EIS system provided immobilization of the
prostate gland highly comparable to the immobilization
provided by an ERB when used in hypofractionated SABR
of the prostate. The system does not adversely impact tar-
get and OAR dosimetry, thereby allowing a means of spar-
ing of rectal tissue while simultaneously delivering high
fractional doses of radiation. Future evaluations using MR
imaging for more accurate delineation of rectal wall tissue
will provide a clearer picture of the dosimetric impacts of
the EIS system in the high-dose regions. The adoption of
this system has the potential to greatly improve the accur-
acy of prostate SABR delivery for patients with localized
prostate cancer.
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